Preview

Ожирение и метаболизм

Расширенный поиск

Лечение сахарного диабета 2-го типа тиаглитазонами; влияние на состояние сердечно-сосудистой системы

https://doi.org/10.14341/2071-8713-5221

Полный текст:

Об авторе

A N Britov



Список литературы

1. American Diabetes Association Standards of medical care in diabetes Diabetes Care 2004; 27(Suppl 1): S15-S35.

2. Guidelines on diabetes, prediabetes, and cardiovascular diseases: full texst. European Heart Journal Supplements, 2007, v. 9, Suppl. C.

3. Killilea T. Long-term Consequences of Type 2 Diabetes Mellitus: Economic Impact on Society and Managed Care. Am J Manag Care, 2002, 8 (16): S441-S449.

4. Secree R., Shaw J., Zimmet P.. Diabetes and impaired glucose tolerance: prevalence and projections In: Allgot B., Gan D., King H., eds. Diabetes atlas. Brussels: International. Diabetes Federation, 2003: 17-71.

5. World Health Organization: «The World Health Report 1998. Life in 21st Century-a Vision for ALL», Geneva: WHO, 1998.

6. The DECODE Study Group. Age and sex specific prevalence of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care; 2003, 26: 61-69.

7. Reaven G.M. Insulin resistance and its consequences: type 2 diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott Williams & Wilkins; 2000, р. 604-615.

8. Hollenbeck C., Reaven G.M. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab, 1987, 64: 1169-1173.

9. Reaven G.M., Brand R.J., Chen I.D., et al. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993, 42: 1324-1332

10. Nakagawa T., Hu H., Zharikov S. et al. A cousal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006; 290: F625-F631. 7. 7. 16

11. Johnson R.J., Feig D.I., Herrera-Acosta J., et al. Resurrection of uric acid as a cousal risk factor in essential hypertension. Hypertension, 2005; 45:18-20.

12. Gao X., Qi L., Qiao N., et al. Intake of added sugar and sugar-sweetened drink and serum uric acid concentration in US men and women. Hypertension, 2007; 50: 306-312.

13. Unwin N., Shaw J., Zimmet P., Alberti K.G. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723.

14. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351: 1755-1762, 1998

15. Almind K., Doria A., Kahn C.R. Putting the genes for type II diabetes on the map. Nat Med 2001; 7: 277-279.

16. Froguel P., Velho G. 2001 Genetic determinants of type 2 diabetes. Recent Prog Horm Res 56:91-105.

17. Bruce D.G., Shishilm D.J., Storlien L.H., Kraegen E.W. Phisiological importance of deficiency in early prandial insulin secession in non-insulin dependent diabetes. Diabetes, 1988; 37:736-744.

18. UKPDS 16, UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes, 1995; 44: 1249-1258.

19. Tuomiletto J., Lindstrom J., Eriksson J.G et al. Prevention of type 2 diabetes mellitus by change in life style among subjects with impaired glucose tolerance. N Engl Med J, 2001; 344: 1343-1350.

20. Diabetes Prevention Research Group. Impact of intensive life style and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Programme. Diabetes Care, 2005; 28: 888-894.

21. Centers for Disease Control (CDC) and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, Ga: US Department of Health and Human Services, CDC and Prevention; 2005.

22. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl Med J, 2003; 348:383-393.

23. Testa M.A., Simonson D.C. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled double-bind trial. JAMA, 1998; 280:1490-1496.

24. American Diabetes Association (ADA). Standards of Medical care in Diabetes. Diabetes Care. 2007b; 30 (Suppl 1): S4-S41.

25. UKPDS 33, UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet,1998; 352:837-853.

26. Ohkubo Y., Kishikawa H., Araki E. et al. Intensitive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice 1995;28: 103-117.

27. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.

28. Knowler W.C., Barrett-Connor E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.

29. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.

30. Lebovitz H.E. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2001; 86:280-288.

31. Lebovitz H.E. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology & Metabolism. 2001; 86: 280-288.

32. Lupi R., Del G.S., Marselli L., et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E560-E567.

33. Finegood D.T., McArthur M.D., Kojwang D., et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.

34. Leiter L.A. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med 2005; 22: 963-972.

35. Xiang A.H., Peters R.K., Kjos S.L., et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 2004; 89: 2846-2851.

36. Young P.W., Cawthorne M.A., Coyle P.J., et al. Repeat treatment of obese mice with BRL49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. Diabetes 1995; 44: 1087-1092.

37. Miyazaki Y., Matsuda M., Mahankali A., et al. Mechanisms of glucose-lowering effect by rosiglitazone in patients with type 2 diabetes. Diabetes 2001; 50 (Supplement 2):A126.

38. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein H.C., Yusef S., Bosch J. et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 2006a; Vol 368(9541): 1096-1105.

39. Charbonnel B. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 year of treatment in type 2 diabetic subjects. Diabetes. 1999; 48: A191.

40. Wolfenbuttel B.H. Addition of low dose rosiglitazone to sulfonylurea therapy improves glycemic control in type 2 diabetic subjects. Diabetic Medicine. 2000; 17: 40-47.

41. Fonseca V. Effect of metformin and rosiglitazone combination therapy in subjects with type 2 diabetes mellitus. JAMA. 2000; 283 (13): 1695-1702.

42. Raskin P. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001; 24(7): 1226-1232.

43. Kahn C.R., Chen L., Cohen S.E. Intravelling the mechanism of action of Thiazolidinediones. J Clin Invest, 2000; 106: 1305-1397.

44. Kahn S.E., Haffner S.M., Heise, M.A., et al. Glycemic Durability of RSG, Metformin, or Glyburide Monotherapy. N Engl J Med. 2006; 355: 2427-2443.

45. Smith S., Boam D.S., Cawthorne M.A., et al. Rosiglitazone improves insulin sensitivity and reduces hyperexpression of insulin and amylin mRNAs in pancreatic islets. Diabetes 1998; 47 (Supplement 1): A94.

46. Dailey G.E., Noor M.A., Park J.S., Bruce S., Fiedorek F.T. Glycemic control with gly-buride/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004. 116: 223-9.

47. Natali A., Baldeweg S., Toschi E. et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004; 27: 1349-1357.

48. Negro R., Mangieri T., Dazzi D. et al. Rosiglitazone effects on blodd pressure and metabolic parameters in nondipper diabetic patients. Diab Res & Clin Pract. 2005;70: 20-25

49. Raji A., Seely E.W., Bekins S.A., et al. RSG improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003; 26:172-178.

50. Sarafidis P.A., Lasaridisa A.N., Nilssonb P.M. et al. Ambulatory blood pressure reduction after RSG treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. Journal of Hypertension. 2004; 22: 1769-1777.

51. Stratton I.M., Cull C.A., Adler A.I., et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006; 49 (8): 1761-1769.

52. Bakris G.L. Microalbuminuria: What is it? Why is it important? What should be done about it? Journal of Clin Hypertension, 2001; 3:99-102.

53. Raskin P., Dole J.F., Rappaport E.B. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (T2D). Diabetes, 1999; 48 (Supplement 1): A94.

54. Malinowski J.M., Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus; a critical review. Clin Thier. 2000;22:1151-1168.

55. Wagstaff A.J., Goa K.L. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002; 62: 1805-1837.

56. Carey D.G., Cowin G.J., Galloway G.J., et al. Effect of RSG on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients. Obesity Research. 2002;.10:.1008-1015.

57. Virtanen K.A., Hоlsten K., Parkkola R. et al. Differential Effects of Rosiglitazone and Metformin on Adipose Tissue Distribution and Glucose Uptake in Type 2 Diabetic Subjects. Diabetes. 2003; 52: 283-290.

58. Tiikkainen M., Hakkinen A.-M., Korsheninnikova E., et al. Effects of RSG and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients With Type 2 Diabetes. Diabetes. 2004; 53: 2169-2176.

59. Kelley D.E., McKolanis T.M., Kelley C.A. Comparative effects of rosiglitazone and metformin on fatty and visceral adiposity in type 2 diabetes mellitus. Diabetes, 2002; 51(Suppl. 2): A53.

60. Cardiovascular Safety of Rosiglitazone. Endocrinologic and Metabolic Drugs Advisory Committee. Drug Safety and Risk Management Advisory Committee. Meeting on July 30, 2007 Prepared by: GlaxoSmithKline Philadelphia, PA, USA.

61. Angulo P., Lindor K.D. Treatment of non-alcoholic steatohepatitis. Best practice and research. Clin. Gastroenterol. 2002; 16(5): 797-810.

62. Browning J.D. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387-1395.

63. New Safety Information on Diabetes Drug Rosiglitazone; www.fda.gov/OHRMS/DOCKETS/98fr/E7-10850.htm <http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-10850.htm>

64. Цитировано по <http://www.diabet-news.ru/addinfo/index.php?id1=1587>

65. Цитировано по <http://www.dentalplans.com>/articles/Deaths%20Halt%20Part%20of%20Large


Для цитирования:


Britov A.N. Лечение сахарного диабета 2-го типа тиаглитазонами; влияние на состояние сердечно-сосудистой системы. Ожирение и метаболизм. 2008;5(4):11-17. https://doi.org/10.14341/2071-8713-5221

For citation:


. Lechenie sakharnogo diabeta 2-go tipa tiaglitazonami; vliyanie na sostoyanie serdechno-sosudistoy sistemy. Obesity and metabolism. 2008;5(4):11-17. (In Russ.) https://doi.org/10.14341/2071-8713-5221

Просмотров: 117


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)